(Q30645037)

25 June 2017

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials (English)

1 reference

systemic lupus erythematosus

25 June 2017

phase III clinical trial

0 references

0 references

1 reference

1 reference

4

Roger A Levy

1 reference

25 June 2017

Ronald van Vollenhoven

2

object named as

Ronald F van Vollenhoven

0 references

Ricard Cervera i Segura

6

object named as

Ricard Cervera

1 reference

25 June 2017

1

Michelle A Petri

1 reference

25 June 2017

Jill Buyon

3

1 reference

25 June 2017

Sandra V Navarra

5

1 reference

25 June 2017

Z John Zhong

7

1 reference

25 June 2017

William W Freimuth

8

1 reference

25 June 2017

BLISS-52 and BLISS-76 Study Groups

9

1 reference

25 June 2017

1 August 2013

1 reference

25 June 2017

Arthritis & Rheumatology

1 reference

25 June 2017

65

1 reference

25 June 2017

8

1 reference

25 June 2017

2143-2153

1 reference

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

25 June 2017

1 reference

Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study

21 January 2018

1 reference

A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus

21 January 2018

1 reference

Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus

21 January 2018

1 reference

Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study

21 January 2018

1 reference

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

21 January 2018

1 reference

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort.

21 January 2018

1 reference

Combined oral contraceptives in women with systemic lupus erythematosus

21 January 2018

1 reference

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study

21 January 2018

1 reference

Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus

21 January 2018

1 reference

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study

21 January 2018

1 reference

The impact of flare on disease costs of patients with systemic lupus erythematosus.

21 January 2018

1 reference

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

From BILAG to BLIPS--disease activity assessment in lupus past, present and future

21 January 2018

1 reference

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus

21 January 2018

1 reference

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

21 January 2018

1 reference

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

21 January 2018

1 reference

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

21 January 2018

1 reference

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group

21 January 2018

1 reference

Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.37995

1 reference

25 June 2017

1 reference